Ovarian Cancer

Far less common than breast cancer, but with a higher mortality rate, sufferers of ovarian cancer are experiencing significant unmet needs. There are therefore considerable market opportunities for drug designers and manufacturers in this life-saving sector of the pharmaceutical industry. In this section a host of cutting edge reports provide valuable insight into key markets such as China and the US, the latest drug development activities and the market trends (including sales, pricing and forecasts) for specific drugs like Doxil, Caelyx, Yondelis and Paclitaxel. You can also purchase reports that feature the latest strategies of major and niche industry players such as Alza Corporation, Amgen, Bristol-Myers Squibb, Cell Therapeutics, Genentech, GlaxoSmithKline, Immunogen, Ivax, OSI Pharmaceuticals and Raven Biotechnologies.
Show Less ... more

• Ovarian Cancer Drug Pipeline Update 2013

  EURO€ 1,499.00USD$ 1,950.00GBP£ 1,261.00AUD$ 1,907.00JPY¥ 192,545.00SEK 12 804,00CHF 1'838.00CAD$ 1,987.00 Bioseeker, Apr 2013
  With nearly 60,000 cases of ovarian cancer being diagnosed in the seven major markets each year, this cancer type is by no means small and therefore it remains an important secondary indication for...

• Global Ovarian Cancer Pipeline Capsule - 2013

  EURO€ 530.00USD$ 690.00GBP£ 446.00AUD$ 675.00JPY¥ 68,126.00SEK 4 530,00CHF 650.00CAD$ 703.00 Commercial Insights, Apr 2013 , Pages: 25
  Fore Pharma’s latest report ‘Global Ovarian Cancer Pipeline Capsule – 2013’ provides up-to-date information on key Research and Development (R&D) activities in the global ovarian cancer market. It covers...

• Ovarian Cancer (Event Driven)

  EURO€ 11,530.00USD$ 15,000.00GBP£ 9,700.00AUD$ 14,671.00JPY¥ 1,480,995.00SEK 98 488,00CHF 14'138.00CAD$ 15,285.00 Decision Resources, Inc, Nov 2012 , Pages: 177
  Owing to the lack of screening programs across the markets under study, ovarian cancer (CaO) typically goes undetected until advanced-stage disease, when prognosis is poor Chemotherapies used to treat...

• Ovarian Cancer - Pipeline Review, H2 2012

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 Global Markets Direct, Oct 2012 , Pages: 449
  Ovarian Cancer – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Ovarian Cancer - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Metastatic Ovarian Cancer - Pipeline Review, H2 2012

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Oct 2012 , Pages: 45
  Metastatic Ovarian Cancer – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Metastatic Ovarian Cancer - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline....

• 09 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

  EURO€ 153.00USD$ 199.00GBP£ 129.00AUD$ 195.00JPY¥ 19,648.00SEK 1 307,00CHF 188.00CAD$ 203.00 Life Science Intelligence, Sep 2012
  This report includes details on 30 emerging medical technology companies that have been identified by LSI's in-house research team in September 2012 All companies include technology, market(s), key...

• Chinese Markets for Ovarian Cancer Treatment Drugs

  EURO€ 4,280.00USD$ 4,000.00GBP£ 2,432.00AUD$ 5,823.00JPY¥ 490,826.00SEK 34 516,00CHF 5'745.00CAD$ 5,347.00 AMID Co, Sep 2012 , Pages: 238
  China's demand for ovarian cancer treatment drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's...

• Global Ovarian Cancer Drugs Market 2011-2015

  EURO€ 1,153.00USD$ 1,500.00GBP£ 970.00AUD$ 1,467.00JPY¥ 148,099.00SEK 9 849,00CHF 1'414.00CAD$ 1,528.00 Infiniti Research Limited, Aug 2012 , Pages: 36
  TechNavio's analysts forecast the Global Ovarian Cancer Drugs market to grow at a CAGR of 13 1 percent over the period 2011-2015 One of the key factors contributing to this market growth is the increasing...

• Disease and Therapy Review: Ovarian Cancer

  EURO€ 1,065.00USD$ 995.00GBP£ 605.00AUD$ 1,449.00JPY¥ 122,093.00SEK 8 586,00CHF 1'429.00CAD$ 1,330.00 Timely Data Resources, Inc, Aug 2012 , Pages: 14
  The Ovarian Cancer Disease and Therapy Review provides an overview of ovarian cancerm, with incidence, prevalence and mortality numbers and percentages for major countries worldwide, as well as information...

• 06 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

  EURO€ 304.00USD$ 395.00GBP£ 255.00AUD$ 386.00JPY¥ 39,000.00SEK 2 594,00CHF 372.00CAD$ 402.00 Life Science Intelligence, Jun 2012 , Pages: 40
  This report includes details on 39 emerging medical technology companies that have been identified by LSI's in-house research team in June 2012 All companies include technology, market(s), key executive,...

• 05 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

  EURO€ 304.00USD$ 395.00GBP£ 255.00AUD$ 386.00JPY¥ 39,000.00SEK 2 594,00CHF 372.00CAD$ 402.00 Life Science Intelligence, May 2012 , Pages: 45
  This report includes details on 41 emerging medical technology companies that have been identified by LSI's in-house research team in May 2012 All companies include technology, market(s), key executive,...

• 04- 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

  EURO€ 304.00USD$ 395.00GBP£ 255.00AUD$ 386.00JPY¥ 39,000.00SEK 2 594,00CHF 372.00CAD$ 402.00 Life Science Intelligence, Apr 2012 , Pages: 38
  This report includes details on 37 emerging medical technology companies that have been identified by LSI's in-house research team in April 2012 All companies include technology, market(s), key executive,...

• 03 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

  EURO€ 304.00USD$ 395.00GBP£ 255.00AUD$ 386.00JPY¥ 39,000.00SEK 2 594,00CHF 372.00CAD$ 402.00 Life Science Intelligence, Mar 2012 , Pages: 81
  This report includes details on 61 emerging medical technology companies that have been identified by LSI's in-house research team in March 2012 All companies include technology, market(s), key executive,...

• 02 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

  EURO€ 304.00USD$ 395.00GBP£ 255.00AUD$ 386.00JPY¥ 39,000.00SEK 2 594,00CHF 372.00CAD$ 402.00 Life Science Intelligence, Feb 2012 , Pages: 95
  This report includes details on 43 emerging medical technology companies that have been identified by LSI's in-house research team in February 2012 All companies include technology, market(s), key executive,...

• Doxil/Caelyx (Ovarian Cancer) - Analysis and Forecasts to 2020

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 GlobalData, Jan 2012 , Pages: 32
  Doxil/Caelyx (Ovarian Cancer) - Analysis and Forecasts to 2020 Summary GlobalData’s pharmaceuticals report, “Doxil/Caelyx (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Doxil/Caelyx sales...

• Global Ovarian Cancer Drug Pipeline Capsule - 2012

  EURO€ 323.00USD$ 420.00GBP£ 272.00AUD$ 411.00JPY¥ 41,468.00SEK 2 758,00CHF 396.00CAD$ 428.00 Fore Pharma, Jan 2012 , Pages: 13
  Fore Pharma’s latest report ‘Global Ovarian Cancer Drug Pipeline Capsule – 2012’ is an outline of all the key research and development (R&D) activities of the global ovarian cancer drug market. It covers...

• 01 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

  EURO€ 304.00USD$ 395.00GBP£ 255.00AUD$ 386.00JPY¥ 39,000.00SEK 2 594,00CHF 372.00CAD$ 402.00 Life Science Intelligence, Jan 2012 , Pages: 101
  This report includes details on 47 emerging medical technology companies that have been identified by LSI's in-house research team in January 2012 All companies include technology, market(s), key executive,...

• Paclitaxel (Ovarian Cancer) - Analysis and Forecasts to 2020

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 GlobalData, Sep 2011 , Pages: 36
  Paclitaxel (Ovarian Cancer) - Analysis and Forecasts to 2020 Summary GlobalData’s pharmaceuticals report, "Paclitaxel (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Paclitaxel sales forecasts...

• Farletuzumab (Ovarian Cancer) - Analysis and Forecasts to 2020

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 GlobalData, Sep 2011 , Pages: 32
  Farletuzumab (Ovarian Cancer) - Analysis and Forecasts to 2020 Summary GlobalData’s pharmaceuticals report, “Farletuzumab (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Farletuzumab sales...

• Karenitecin (Ovarian Cancer) - Analysis and Forecasts to 2020

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 GlobalData, Sep 2011 , Pages: 32
  Karenitecin (Ovarian Cancer) - Analysis and Forecasts to 2020 Summary GlobalData’s pharmaceuticals report, "Karenitecin (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Karenitecin sales...

• Carboplatin (Ovarian Cancer) - Analysis and Forecasts to 2020

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 GlobalData, Sep 2011 , Pages: 33
  Carboplatin (Ovarian Cancer) - Analysis and Forecasts to 2020 Summary GlobalData’s pharmaceuticals report, "Carboplatin (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Carboplatin sales...

• Votrient (Ovarian Cancer) - Analysis and Forecasts to 2020

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 GlobalData, Sep 2011 , Pages: 31
  Votrient (Ovarian Cancer) - Analysis and Forecasts to 2020 Summary GlobalData’s pharmaceuticals report, “Votrient (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Votrient sales forecasts...

• Gemzar (Ovarian Cancer) - Analysis and Forecasts to 2020

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 GlobalData, Sep 2011 , Pages: 31
  Gemzar (Ovarian Cancer) - Analysis and Forecasts to 2020 Summary GlobalData’s pharmaceuticals report, “Gemzar (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Gemzar sales forecasts for...

• Cisplatin (Ovarian Cancer) - Analysis and Forecasts to 2020

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 GlobalData, Sep 2011 , Pages: 33
  Cisplatin (Ovarian Cancer) - Analysis and Forecasts to 2020 Summary GlobalData’s pharmaceuticals report, "Cisplatin (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Cisplatin sales forecasts...

• Opaxio (Ovarian Cancer) - Analysis and Forecasts to 2020

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 GlobalData, Sep 2011 , Pages: 25
  Opaxio (Ovarian Cancer) - Analysis and Forecasts to 2020 Summary GlobalData’s pharmaceuticals report, “Opaxio (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Opaxio sales forecasts for...

• Paclical (Ovarian Cancer) - Analysis and Forecasts to 2020

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 GlobalData, Sep 2011 , Pages: 32
  Paclical (Ovarian Cancer) - Analysis and Forecasts to 2020 Summary GlobalData’s pharmaceuticals report, "Paclical (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Paclical sales estimates...

• Avastin (Ovarian Cancer) - Analysis and Forecasts to 2020

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 GlobalData, Sep 2011 , Pages: 33
  Avastin (Ovarian Cancer) - Analysis and Forecasts to 2020 Summary GlobalData’s pharmaceuticals report, “Avastin (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Avastin sales forecasts...

• Vargatef (Ovarian Cancer) - Analysis and Forecasts to 2020

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 GlobalData, Sep 2011 , Pages: 32
  Vargatef (Ovarian Cancer) – Analysis and Forecasts to 2020 Summary GlobalData’s pharmaceuticals report, “Vargatef (Ovarian Cancer) - Analysis and Forecats to 2020” provides Vargatef sales forecasts...

• Recentin (Ovarian Cancer) - Analysis And Forecasts to 2020

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 GlobalData, Sep 2011 , Pages: 31
  Recentin (Ovarian Cancer) – Analysis And Forecasts to 2020 Summary GlobalData’s pharmaceuticals report, “Recentin (Ovarian Cancer) – Analysis and Forecasts to 2020” provides Recentin sales estimates...

• Hycamtin (Ovarian Cancer) - Analysis and Forecasts to 2020

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 GlobalData, Sep 2011 , Pages: 34
  Hycamtin (Ovarian Cancer) - Analysis and Forecasts to 2020 Summary GlobalData’s pharmaceuticals report, “Hycamtin (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Hycamtin sales forecasts...

• AMG 386 (Ovarian Cancer) - Analysis and Forecasts to 2020

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 GlobalData, Sep 2011 , Pages: 32
  AMG 386 (Ovarian Cancer) - Analysis and Forecasts to 2020 Summary GlobalData’s pharmaceuticals report, "AMG 386 (Ovarian Cancer) - Analysis and Forecasts to 2020” provides AMG 386 sales forecasts...

• EC145 (Ovarian Cancer) - Analysis and Forecasts to 2020

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 GlobalData, Sep 2011 , Pages: 29
  EC145 (Ovarian Cancer) - Analysis and Forecasts to 2020 Summary GlobalData’s pharmaceuticals report, “EC145 (Ovarian Cancer) - Analysis and Forecasts to 2020” provides EC145 sales estimates for US,...

• Yondelis (Ovarian Cancer) - Analysis and Forecasts to 2020

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 GlobalData, Sep 2011 , Pages: 32
  Yondelis (Ovarian Cancer) - Analysis and Forecasts to 2020 Summary GlobalData’s pharmaceuticals report, “Yondelis (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Yondelis sales forecasts...

• Disease and Therapy Review: Ovarian Cancer

  EURO€ 1,065.00USD$ 995.00GBP£ 605.00AUD$ 1,449.00JPY¥ 122,093.00SEK 8 586,00CHF 1'429.00CAD$ 1,330.00 Timely Data Resources, Inc, Sep 2011 , Pages: 13
  Disease and Therapy Reviews were developed to provide a basic understanding of the key facts about a disease and market in a quick, easy-to-read format These reports are prepared by the senior market...

• Polycystic Ovarian Syndrome Global Clinical Trials Review, Q2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Jun 2011 , Pages: 55
  Polycystic Ovarian Syndrome Global Clinical Trials Review, Q2, 2011 Summary GlobalData's clinical trial report, “Polycystic Ovarian Syndrome Global Clinical Trials Review, Q2, 2011" provides data...

• 2011 Global Markets for External Radiation Therapy

  EURO€ 4,996.00USD$ 6,500.00GBP£ 4,203.00AUD$ 6,357.00JPY¥ 641,764.00SEK 42 678,00CHF 6'126.00CAD$ 6,623.00 Life Science Intelligence, May 2011 , Pages: 129
  2011 Global Markets for External Radiation Therapy is a comprehensive market intelligence solution designed for senior executives who are looking for: - High quality, granular, deeply segmented data...

• 2011 O.U.S. Markets For External Radiation Therapy

  EURO€ 2,998.00USD$ 3,900.00GBP£ 2,522.00AUD$ 3,814.00JPY¥ 385,059.00SEK 25 607,00CHF 3'676.00CAD$ 3,974.00 Life Science Intelligence, May 2011 , Pages: 84
  2011 O U S Markets For External Radiation Therapy is a comprehensive market intelligence solution designed for senior executives who are looking for: - High quality, granular, deeply segmented data...

• 2011 U.S. Markets for External Radiation Therapy

  EURO€ 2,998.00USD$ 3,900.00GBP£ 2,522.00AUD$ 3,814.00JPY¥ 385,059.00SEK 25 607,00CHF 3'676.00CAD$ 3,974.00 Life Science Intelligence, May 2011 , Pages: 66
  2011 U S Markets for External Radiation Therapy is a comprehensive market intelligence solution designed for senior executives who are looking for: - High quality, granular, deeply segmented data -...

• Stakeholder Opinions: Ovarian Cancer - Approaching the era of molecular targeted therapy

  EURO€ 2,921.00USD$ 3,800.00GBP£ 2,457.00AUD$ 3,717.00JPY¥ 375,185.00SEK 24 950,00CHF 3'582.00CAD$ 3,872.00 Datamonitor, Jul 2010 , Pages: 93
  Introduction Despite advances in the management of the disease, outcomes remain poor for patients with advanced epithelial ovarian cancer. The high level of unmet need, coupled with the large size...

• Thought Leader Insight & Analysis Report - Ovarian Cancer Q1 2010

  EURO€ 5,765.00USD$ 7,500.00GBP£ 4,850.00AUD$ 7,336.00JPY¥ 740,497.00SEK 49 244,00CHF 7'069.00CAD$ 7,642.00 Medpredict, Feb 2010 , Pages: 146
  Ovarian cancer is only one tenth as common as breast cancer, but the mortality associated with ovarian cancer is higher There are 250,000 new cases diagnosed each year in the US, and at least 15,000...

• Emerging Diagnostic Biomarkers in Ovarian Cancer

  EURO€ 855.00USD$ 1,112.00GBP£ 719.00AUD$ 1,088.00JPY¥ 109,840.00SEK 7 305,00CHF 1'049.00CAD$ 1,134.00 Decision Resources, Inc, Jul 2006 , Pages: 25
  Worldwide, ovarian cancer (CaO) is the leading cause of death from gynecological cancer and the fourth most common cause of cancer death in women In 2006, according to the American Cancer Society, 20,180...

• Ovarian Cancer Therapeutics - Global Strategic Business Report

  EURO€ 3,407.00USD$ 3,850.00GBP£ 2,272.00AUD$ 5,324.00JPY¥ 461,687.00SEK 30 287,00CHF 5'070.00CAD$ 4,938.00 Global Industry Analysts, Inc, Feb 2006 , Pages: 248
  This report analyzes the worldwide markets for Ovarian Cancer Therapeutics in Millions of US$ The major product segments analyzed are Localized Ovarian Cancer Therapeutics, Metastatic Ovarian Cancer...

• U.S. Emerging Ovarian Cancer Therapeutics Markets

  EURO€ 3,036.00USD$ 3,950.00GBP£ 2,554.00AUD$ 3,863.00JPY¥ 389,995.00SEK 25 935,00CHF 3'723.00CAD$ 4,025.00 Frost & Sullivan, Jan 2002
  High Relapse Rate Drives Demand for Expanded Treatment Options Though chemotherapy is effective in achieving remission in most ovarian cancer patients, remission often lasts less than two years....